Expert Ratings for Reata Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Reata Pharmaceuticals (NASDAQ:RETA) in the last quarter. According to 7 analysts offering 12-month price targets in the last 3 months, Reata Pharmaceuticals has an average price target of $120.0, an increase of 24.48% from the previous average price target of $96.40.
July 24, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have provided bullish ratings for Reata Pharmaceuticals, with an increased average price target of $120.0.
The bullish ratings and increased price target indicate a positive outlook for Reata Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100